| Title |
Treatment of convulsive and nonconvulsive status epilepticus
|
|---|---|
| Published in |
Current Treatment Options in Neurology, July 2005
|
| DOI | 10.1007/s11940-005-0035-x |
| Pubmed ID | |
| Authors |
Trudy Pang, Lawrence J. Hirsch |
| Abstract |
Status epilepticus (SE) should be treated as quickly as possible with full doses of medications as detailed in a written hospital protocol. Lorazepam is the drug of choice for initial treatment. If intravenous access is not immediately available, then rectal diazepam or nasal or buccal midazolam should be given. Prehospital treatment of seizures by emergency personnel is effective and safe, and may prevent cases of refractory SE. Home treatment of prolonged seizures or clusters with buccal, nasal, or rectal benzodiazepines should be considered for all at-risk patients. Nonconvulsive SE is underdiagnosed. An electroencephalogram should be obtained immediately in anyone with unexplained alteration of behavior or mental status and after convulsive SE if the patient does not rapidly awaken. Delay in diagnosis of SE is associated with a worse outcome and a higher likelihood of poor response to treatment. For refractory SE, continuous intravenous midazolam and propofol (alone or in combination) are rapidly effective. Randomized trials are needed to determine the best treatment for SE after lorazepam. |
Mendeley readers
The data shown below were compiled from readership statistics for 60 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Mexico | 1 | 2% |
| Unknown | 58 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 25% |
| Other | 8 | 13% |
| Student > Bachelor | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Professor > Associate Professor | 5 | 8% |
| Other | 12 | 20% |
| Unknown | 10 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 48% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Neuroscience | 3 | 5% |
| Computer Science | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2023.
All research outputs
#3,214,946
of 26,017,215 outputs
Outputs from Current Treatment Options in Neurology
#62
of 503 outputs
Outputs of similar age
#6,452
of 70,617 outputs
Outputs of similar age from Current Treatment Options in Neurology
#1
of 3 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 503 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 70,617 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them